A question on #Drugs #Prices tabled by Sadik Al-Hassan on 18-07-2025 has been answered by Karin Smyth.

Heading: Drugs: Prices
Question ID: 1824866
UIN: 69183
House: Commons
Date tabled: 2025-07-18
Asking Member ID: 5312
Asking Member display name: Sadik Al-Hassan
Asking Member handle:
Asking Member Twitter reference: Sadik Al-Hassan
Member interest: false
Question text: To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 18 June 2025 to Question 54542 on Drug Prices, how many of the commercial arrangements involving indications-specific pricing were for indications for (a) rare and (b) ult
Is named day: false
Date of holding answer:
Date answered: 2025-08-04
Date answer corrected:
Is holding answer: false
Is correcting answer: false
Answering Member ID: 4444
Answering Member display name: Karin Smyth
Answering Member handle: karinsmyth
Answering Member Twitter reference: @karinsmyth
Correcting Member ID:
Correcting Member display name:
Correcting Member handle:
Correcting Member Twitter reference:
Answer text: Between January 2020 and March 2025, NHS England entered into 62 commercial agreements involving indication-specific pricing for cancer indications. Of these:60 were for indications classified as rare; andof those 60, two were for indications classified a...
Original answer text:
Comparable answer text:
Answering body ID: 17
Answering body name: Department of Health and Social Care
Tweeted: true